Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Titan: Apart from many firsts... - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Dec 19, 2007

    Titan: Apart from many firsts...

    From starting out in a joint venture with the Tamil Nadu Industrial Development Corporation in 1984 for manufacturing and marketing of watches, to being one of the firsts to foray into branded jewellery, Titan Industries is one of the early entrants into the lucrative prescription eyewear business to cash-in on the retail boom in a burgeoning economy. Over a period of time the company has leveraged its assets and capabilities by venturing into jewellery business, precision engineering, sunglasses and now prescription eyewear.

    Although Titan launched its eyewear business in 2007, the company had actually forayed into the business way back in FY05 itself by launching sunglasses under the Fast Track brand. This segment has clocked revenues worth Rs 250 m in FY07 (1.2% of consolidated sales). The first prescription eyewear store (the pilot project) was opened in 4QFY07 and now has 5 Titan eye+ outlets (end of September 2007) and expects to take its total no of stores to 14 by the end of FY08.

    Rationale behind the foray
    India is the world's second most populous country with over 1 bn people. The current Indian prescription eyewear market is sizeable with nearly 30% of the over 1 bn population requiring vision correction. However, this immense market is characterised by a few indigenous optical brands operating in the mid to premium segment and several other unorganised players who offer low-priced products. As such, the category offers a huge potential in terms of brand recognition, style and consistent quality to consumers.

    The scope...
    The actual market for prescription eyewear comprises of the people who have recognised the need for vision correction amongst the total population who need vision correction. This cluster works out to only 25% of the total potential market translating into approximately 85 m users of prescription eyewear product.

    This segment of lifestyle business is comparable to watch industry as the consumer typically change their glasses or frames once in three to four years. Repeat purchases are made owing to adolescence or old age. Every year 25 to 35 m units are sold in the range of Rs 1,500 to 1,800 and this market is growing at the rate of 15% to 20% annually. Almost everyone over 40 years of age needs vision correction.

    The demand drivers

    • According to 2001 census of India, the population of India is growing at a rate of 2.1% approximately. This only indicates the incremental demand for the eyewear products as new consumers get added to the existing huge base of 1 bn people.
    • On account of changing lifestyle and improper diet the need for vision correction is rising day by day. Penetration of TV and computers has further fuelled the demand for eyewear products as more people now require vision correction owing to continuous stress to eye or as a precaution. Owing to literacy and the urbanization, a new cluster of consumers are getting added to the existing base, leading to incremental demand for eyewear products.

    Where lies Titan's role in the value chain?
    The business, which is comparable to watch industry, is a high margin business at retail level. As it is profitable to be a retailer, the company will not indulge in manufacturing of lenses and frames. Thus Titan will focus on its core competencies, which include designing retailing, servicing and marketing the product. It will outsource its eyewear requirements such as lenses, frames and accessories from reputed domestic and international vendors on long-term contract basis. While frames for lenses and sunglasses will be designed in-house.

    In order to gain a dominant position in the optical solutions market, the company also plans to showcase eyewear products such as sunglasses of leading international brands. For the same, the company has tied up with Essilor, the world's largest lens manufacturer, for supply of optical lenses.

    The way forward...
    The foray into prescription eyewear business is Titan's third major line of consumer business, after watches and jewellery. Titan has envisaged plans to be a dominant player in the mid-priced segment offering optical solutions for varying consumer needs. The stores will carry frames bearing the Titan brand as well as the Eye+ and Dash brands (for children). Apart from this, the Titan Eye+ stores will also sale frames and sunglasses from a host of fashion brands and owned labels.

    As per the company's outlined plans it will eventually open (mainly in A and B segment towns) 150 Eye+ stores and 100 franchisee outlets by 2010. Thus initially the company would be investing approximately Rs 150 to 200 m for setting up the Eye+ stores and expects the stores to clock business worth Rs 150 m in FY08. Going forward, i.e. by 2012, the company expects this business to contribute 15% to the total revenues and account for 20% of the market share.

    Through this eyewear business, Titan will try to gain the first mover advantage and acquire a leadership position by leveraging its well-established retail network and design and marketing capacities.



    Equitymaster requests your view! Post a comment on "Titan: Apart from many firsts...". Click here!


    More Views on News

    Titan: Jewellery Business Lights up the Quarter (Quarterly Results Update - Detailed)

    Aug 10, 2017

    However, growth at these levels are unlikely to be sustainable.

    Avenue Supermarts Ltd. (IPO)

    Mar 7, 2017

    Equitymaster analyses Initial Public Offering (IPO) of Avenue Supermarts Limited.

    Titan: Beating the Demonetisation Blues (Quarterly Results Update - Detailed)

    Feb 14, 2017

    Titan Industries declared its results for the third quarter of financial year 2017 (3QFY17). While topline growth was 14.7% YoY, net profit grew by 13.1% YoY during the quarter. Here is our analysis of the results.

    Titan: Margin Improvement Saves the Day (Quarterly Results Update - Detailed)

    Nov 16, 2016

    Titan Industries declared its results for the second quarter of financial year 2017 (2QFY17). While topline growth was flat, net profit grew by 23.5% YoY during the quarter. Here is our analysis of the results.

    Titan: High Gold Prices Spoil the Show (Quarterly Results Update - Detailed)

    Aug 9, 2016

    Titan Industries declared its results for the first quarter of financial year 2017 (1QFY17). The company reported 3.3% YoY increase in sales, while net profit fell by 16.3% YoY during the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms